With a new minimally invasive blood test, mir
detect offers a technology with high sensitivity and specificity that allows for the early detection of testicular germ cell tumors. This test has the potential to reduce diagnostic operations, adjuvant chemotherapies, redundant cycles of chemotherapy and CT examinations. Therefore, over- and undertreatment or incorrect treatments can be avoided and radiation is reduced improving quality of life for patients.
Location: Germany, Bremen
Investors 2
| Date | Name | Website |
| - | MediVentur... | medi.ventu... |
| - | High-Tech ... | htgf.de |
Mentions in press and media 2
| Date | Title | Description | Source |
| 02.05.2019 | miRdetect Raises Seven-Digit Seed Funding | miRdetect, a Bremen, Germany-based startup that develops a test method for the detection of testicul... | finsmes.co... |
| - | miRdetect Receives Seed Financing – Consortium Invests Seven... | May 2, 2019 Together with BBM and a private investor, High-Tech Gründerfonds (HTGF) is investing a ... | htgf.de/en... |